Sherif Shafik Farag MD

Professor, Medicine, Indiana University School of Medicine

3500 S Lafountain StKokomo, IN 46902
Phone+1 765-776-3500
Fax+1 317-274-5645

Summary

Faculty Profile

IU School of Medicine is the largest medical school in the US and is annually ranked among the top medical schools in the nation by US News & World Report. The

Education & Training

University of MelbournePhD, Medicine, 1991 - 1995
University of Melbourne Faculty of MedicineClass of 1984, MB BS

Certifications & Licensure

IN State Medical License 2006 - 2027
MI State Medical License 2021 - 2027
OH State Medical License 1999 - 2027
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2008-2013
Indianapolis Monthly Castle Connolly, 2009-2011, 2013

Clinical Trials

Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease Start of enrollment: 2003 Dec 01
Completed
Phase 2
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer Start of enrollment: 2006 May 01
Withdrawn
Phase 1, Phase 2
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma Start of enrollment: 2007 May 01
Completed
Phase 1
A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies Start of enrollment: 2007 Aug 01
Terminated
Phase 1
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies Start of enrollment: 2007 Aug 07
Terminated
Phase 2
Sitagliptin Umbilical Cord Blood Transplant Study Start of enrollment: 2009 Mar 01
Completed
Phase 2
Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2 Start of enrollment: 2004 Jan 01
Completed
Selecting a Favorable KIR Donor in Unrelated HCT for AML Start of enrollment: 2011 Jun 01
Completed
Not Applicable
Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) Start of enrollment: 2011 Feb 07
Terminated
Phase 1, Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RECRUITING
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Identification of the Distinct Immune Microenvironment Features Associated with Progression Following High-Dose Melphalan and Autologous Stem Cell Transplant in Multip...
Parvathi Sudha, Travis S Johnson, Habib Hamidi, Ke Yang, Enze Liu
Cancer Immunology Research. 2025-07-02
2 citations
Risk Factors for Solid Organ Graft Failure and Death in Hematopoietic Cell Transplant Recipients Undergoing Solid Organ Transplantation: A Retrospective Center for Int...
Meera Gupta, Michelle L Schoettler, Ruta Brazauskas, Stephanie Bo-Subait, Gabriel Orozco
Transplantation. 2025-06-23
2 citations
Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Retrospective Center for Int...
Meera Gupta, Michelle L Schoettler, Gabriel Orozco, Ruta Brazauskas, Stephanie Bo-Subait
Transplantation. 2025-06-23

Journal Articles

Pretransplant HLA Typing Revealed Loss of Heterozygosity in the Major Histocompatibility Complex in a Patient with Acute Myeloid Leukemia
Gail H Vance, Andrew L Lobashevsky, Sherif S Farag, ScienceDirect

Press Mentions

Community Health Network Names Medical Director of Stem Cell Transplant and Cellular Therapy ProgramJanuary 25th, 2024

Grant Support

Enhancing Engraftment Of Cord Blood By CD26 InhibitionNational Heart, Lung, And Blood Institute2012
Multiple Kinase Target Inhibition With Emnd-2076 In Multiple MyelomaNational Cancer Institute2010–2011
PathologyNational Cancer Institute2006–2010
Leukemia Tissue BankNational Cancer Institute2005–2009
Qms Technology To Deplete T Cell AlloreactivityNational Institute Of Allergy And Infectious Diseases2006–2008
Qms Technology To Deplete T Cell AlloreactivityNational Institute Of Allergy And Infectious Diseases2004–2005
Mtor Inhibition As A Therapeutic Target In MyelomaNational Cancer Institute2004–2005
NK Cell Recognition Of Leukemia Blasts And IL-2 TherapyNational Cancer Institute2003–2004
Innate Immune Cell Therapy With Stem Cell TransplantsNational Cancer Institute2002–2003